Literature DB >> 28235776

Cost-effectiveness of a text message programme for the prevention of recurrent cardiovascular events.

Edward Burn1, Son Nghiem1, Stephen Jan2, Julie Redfern2, Anthony Rodgers2, Aravinda Thiagalingam3,4, Nicholas Graves1, Clara K Chow2,3,4.   

Abstract

OBJECTIVE: To estimate the cost-effectiveness of Tobacco, Exercise and Diet Messages (TEXT ME), a text message-based intervention that provides advice, motivation, information and support to improve health-related behaviours.
METHODS: A lifetime Markov model was used to estimate major vascular events (myocardial infarctions and strokes) avoided, quality-adjusted life years (QALYs) gained, costs to the health system and the incremental cost per QALY gained. The model was informed by data from a randomised controlled trial of TEXT ME, with evidence from systematic reviews and meta-analyses used to estimate the effects of changes in risk factors on the risk of major vascular events. Expected costs and health outcomes were estimated with uncertainty surrounding these characterised using probabilistic sensitivity analysis and a number of scenario analyses.
RESULTS: For a target population of 50 000 patients with documented coronary heart disease, the intervention is expected to lead to 563 fewer myocardial infarctions, 361 fewer strokes and 1143 additional QALYs. TEXT ME is expected to lead to an overall saving of $10.56 million for the health system over the patients' lifetimes. The intervention can therefore be considered cost-saving and health-improving. Neither parameter nor structural uncertainty had a significant impact on the conclusion that TEXT ME is cost-effective.
CONCLUSIONS: The provision of TEXT ME is predicted to lead to better health outcomes and an overall saving in costs for the health system. TRIAL REGISTRATION NUMBER: anzctr.org.au identifier: ACTRN12611000161921. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cost effectiveness; mHealth; secondary prevention of cardiovascular disease; text-messaging interventions

Mesh:

Year:  2017        PMID: 28235776     DOI: 10.1136/heartjnl-2016-310195

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  14 in total

1.  The effects of a lifestyle-focused text-messaging intervention on adherence to dietary guideline recommendations in patients with coronary heart disease: an analysis of the TEXT ME study.

Authors:  Karla Santo; Karice Hyun; Laura de Keizer; Aravinda Thiagalingam; Graham S Hillis; John Chalmers; Julie Redfern; Clara K Chow
Journal:  Int J Behav Nutr Phys Act       Date:  2018-05-23       Impact factor: 6.457

Review 2.  Mobile Phone Technologies in the Management of Ischemic Heart Disease, Heart Failure, and Hypertension: Systematic Review and Meta-Analysis.

Authors:  Praveen Indraratna; Daniel Tardo; Jennifer Yu; Kim Delbaere; Matthew Brodie; Nigel Lovell; Sze-Yuan Ooi
Journal:  JMIR Mhealth Uhealth       Date:  2020-07-06       Impact factor: 4.773

3.  Text messages for primary prevention of cardiovascular disease: the TextMe2 randomised controlled trial protocol.

Authors:  Harry Klimis; Aravinda Thiagalingam; Clara K Chow
Journal:  BMJ Open       Date:  2020-04-26       Impact factor: 2.692

4.  ITM support for patients with chronic respiratory and cardiovascular diseases: a protocol for a randomised controlled trial.

Authors:  Julie Redfern; Karice Hyun; Anna Singleton; Nashid Hafiz; Rebecca Raeside; Lissa Spencer; Bridie Carr; Ian Caterson; John Cullen; Cate Ferry; Karla Santo; Alison Hayes; Regina W M Leung; Simon Raadsma; Jessica Swinbourne; Jin G Cho; Meredith King; Mary Roberts; Cindy Kok; Christine Jenkins; Clara Chow
Journal:  BMJ Open       Date:  2019-03-01       Impact factor: 2.692

Review 5.  mHealth Interventions for Exercise and Risk Factor Modification in Cardiovascular Disease.

Authors:  Ralph Maddison; Jonathan C Rawstorn; Sheikh Mohammed Shariful Islam; Kylie Ball; Sarah Tighe; Nicholas Gant; Robyn M Whittaker; Clara K Chow
Journal:  Exerc Sport Sci Rev       Date:  2019-04       Impact factor: 6.230

6.  Development and piloting of a highly tailored digital intervention to support adherence to antihypertensive medications as an adjunct to primary care consultations.

Authors:  Aikaterini Kassavou; Vikki Houghton; Simon Edwards; James Brimicombe; Stephen Sutton
Journal:  BMJ Open       Date:  2019-01-06       Impact factor: 2.692

7.  The Cost-Effectiveness of Digital Health Interventions on the Management of Cardiovascular Diseases: Systematic Review.

Authors:  Xinchan Jiang; Wai-Kit Ming; Joyce Hs You
Journal:  J Med Internet Res       Date:  2019-06-17       Impact factor: 5.428

8.  TEXT4myBACK - The Development Process of a Self-Management Intervention Delivered Via Text Message for Low Back Pain.

Authors:  Carolina G Fritsch; Paulo H Ferreira; Joanna L Prior; Giovana Vesentini; Patricia Schlotfeldt; Jillian Eyles; Sarah Robbins; Shirley Yu; Kathryn Mills; Deborah A Taylor; Tara E Lambert; Ornella Clavisi; Lisa Bywaters; Clara K Chow; Julie Redfern; Andrew J McLachlan; Manuela L Ferreira
Journal:  Arch Rehabil Res Clin Transl       Date:  2021-04-27

9.  Mobile phone text-messaging interventions aimed to prevent cardiovascular diseases (Text2PreventCVD): systematic review and individual patient data meta-analysis.

Authors:  Sheikh Mohammed Shariful Islam; Andrew J Farmer; Kirsten Bobrow; Ralph Maddison; Robyn Whittaker; Leila Anne Pfaeffli Dale; Andreas Lechner; Scott Lear; Zubin Eapen; Louis Wilhelmus Niessen; Karla Santo; Sandrine Stepien; Julie Redfern; Anthony Rodgers; Clara K Chow
Journal:  Open Heart       Date:  2019-10-09

10.  MEDication reminder APPs to improve medication adherence in Coronary Heart Disease (MedApp-CHD) Study: a randomised controlled trial protocol.

Authors:  Karla Santo; Clara K Chow; Aravinda Thiagalingam; Kris Rogers; John Chalmers; Julie Redfern
Journal:  BMJ Open       Date:  2017-10-08       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.